Abstract
Hematopoietic stem cell transplantation from a healthy donor (allo-HSCT) represents the most potent form of cellular adoptive immunotherapy to treat malignancies. In allo-HSCT, donor T cells are double edge-swords: highly potent against residual tumor cells, but potentially highly toxic, and responsible for graft versus host disease (GVHD), a major clinical complication of transplantation. Gene transfer technologies coupled with current knowledge on cancer immunology have generated a wide range of approaches aimed at fostering the immunological response to cancer cells, while avoiding or controlling GVHD. In this review, we discuss cell and gene therapy approaches currently tested in preclinical models and in clinical trials. Video podcast available: Go to www.immunologicalreviews.com to watch an interview with Guest Editor Dr Carl June.
| Original language | English |
|---|---|
| Pages (from-to) | 165-180 |
| Number of pages | 16 |
| Journal | Immunological Reviews |
| Volume | 257 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 2014 |
Fingerprint
Keywords
- Adoptive cellular immunotherapy
- Allogeneic hematopoietic stem cell transplantation
- CAR
- Gene therapy
- Suicide gene
- TCR
ASJC Scopus subject areas
- Immunology
- Immunology and Allergy
Cite this
Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation. / Cieri, Nicoletta; Mastaglio, Sara; Oliveira, Giacomo; Casucci, Monica; Bondanza, Attilio; Bonini, Chiara.
In: Immunological Reviews, Vol. 257, No. 1, 01.2014, p. 165-180.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation
AU - Cieri, Nicoletta
AU - Mastaglio, Sara
AU - Oliveira, Giacomo
AU - Casucci, Monica
AU - Bondanza, Attilio
AU - Bonini, Chiara
PY - 2014/1
Y1 - 2014/1
N2 - Hematopoietic stem cell transplantation from a healthy donor (allo-HSCT) represents the most potent form of cellular adoptive immunotherapy to treat malignancies. In allo-HSCT, donor T cells are double edge-swords: highly potent against residual tumor cells, but potentially highly toxic, and responsible for graft versus host disease (GVHD), a major clinical complication of transplantation. Gene transfer technologies coupled with current knowledge on cancer immunology have generated a wide range of approaches aimed at fostering the immunological response to cancer cells, while avoiding or controlling GVHD. In this review, we discuss cell and gene therapy approaches currently tested in preclinical models and in clinical trials. Video podcast available: Go to www.immunologicalreviews.com to watch an interview with Guest Editor Dr Carl June.
AB - Hematopoietic stem cell transplantation from a healthy donor (allo-HSCT) represents the most potent form of cellular adoptive immunotherapy to treat malignancies. In allo-HSCT, donor T cells are double edge-swords: highly potent against residual tumor cells, but potentially highly toxic, and responsible for graft versus host disease (GVHD), a major clinical complication of transplantation. Gene transfer technologies coupled with current knowledge on cancer immunology have generated a wide range of approaches aimed at fostering the immunological response to cancer cells, while avoiding or controlling GVHD. In this review, we discuss cell and gene therapy approaches currently tested in preclinical models and in clinical trials. Video podcast available: Go to www.immunologicalreviews.com to watch an interview with Guest Editor Dr Carl June.
KW - Adoptive cellular immunotherapy
KW - Allogeneic hematopoietic stem cell transplantation
KW - CAR
KW - Gene therapy
KW - Suicide gene
KW - TCR
UR - http://www.scopus.com/inward/record.url?scp=84890169660&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84890169660&partnerID=8YFLogxK
U2 - 10.1111/imr.12130
DO - 10.1111/imr.12130
M3 - Article
VL - 257
SP - 165
EP - 180
JO - Immunological Reviews
JF - Immunological Reviews
SN - 0105-2896
IS - 1
ER -